Protagonist Therapeutics (NASDAQ:PTGX) Director Sells $257,000.00 in Stock

Key Points

• Protagonist Therapeutics Director William Waddill sold 4,000 shares of stock for a total of $257,000, resulting in a 43.81% decrease in his ownership.
• The company's stock traded at $65.95 recently, with a market capitalization of $4.10 billion and a price-to-earnings ratio of 94.22.
• Analysts have rated Protagonist Therapeutics with a consensus rating of Buy and a price target of $68.36, with several upgrades from firms like Barclays and JMP Securities.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) Director William Waddill sold 4,000 shares of the company's stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $64.25, for a total transaction of $257,000.00. Following the transaction, the director owned 5,130 shares in the company, valued at approximately $329,602.50. The trade was a 43.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Protagonist Therapeutics Stock Performance

Protagonist Therapeutics stock traded up $0.89 during trading hours on Wednesday, reaching $65.95. 818,313 shares of the company's stock traded hands, compared to its average volume of 1,073,507. Protagonist Therapeutics, Inc. has a fifty-two week low of $33.31 and a fifty-two week high of $66.70. The firm has a market capitalization of $4.10 billion, a price-to-earnings ratio of 94.22 and a beta of 2.22. The firm's 50 day moving average is $57.12 and its 200-day moving average is $52.00.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.02). The company had revenue of $5.55 million during the quarter, compared to the consensus estimate of $8.32 million. Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. Analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PTGX shares. Barclays started coverage on Protagonist Therapeutics in a research note on Wednesday, September 17th. They issued an "overweight" rating and a $72.00 price target for the company. JMP Securities upped their price target on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a "market outperform" rating in a research note on Thursday, August 7th. Wall Street Zen raised Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 8th. Leerink Partners started coverage on Protagonist Therapeutics in a research note on Friday, September 12th. They issued an "outperform" rating and a $73.00 price target for the company. Finally, Leerink Partnrs raised Protagonist Therapeutics to a "strong-buy" rating in a research note on Friday, September 12th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Protagonist Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $68.36.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds have recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new position in shares of Protagonist Therapeutics during the 2nd quarter worth approximately $27,000. Bessemer Group Inc. grew its stake in shares of Protagonist Therapeutics by 171.0% during the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company's stock worth $28,000 after acquiring an additional 318 shares in the last quarter. CWM LLC grew its stake in shares of Protagonist Therapeutics by 201.5% during the 2nd quarter. CWM LLC now owns 609 shares of the company's stock worth $34,000 after acquiring an additional 407 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Protagonist Therapeutics during the 4th quarter worth approximately $48,000. Finally, GAMMA Investing LLC grew its stake in shares of Protagonist Therapeutics by 153.3% during the 1st quarter. GAMMA Investing LLC now owns 1,203 shares of the company's stock worth $58,000 after acquiring an additional 728 shares in the last quarter. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.